Home / Health / New Review Questions Alzheimer's Drug Benefits
New Review Questions Alzheimer's Drug Benefits
12 May
Summary
- Cochrane review finds amyloid drugs offer minimal memory improvement.
- Researchers cite potential brain swelling and bleeding risks.
- Alzheimer's Association disputes review, calling it flawed.
A significant Cochrane review has cast doubt on the effectiveness and safety of amyloid-targeting drugs for Alzheimer's disease. The analysis of 17 trials indicated that while these medications reduce amyloid-beta plaques, they offer negligible improvements in memory decline and dementia severity.
Lead author Francesco Nonino stated that the evidence suggests these drugs do not make a meaningful difference for patients, distinguishing between statistical significance and clinical relevance. The review also highlighted potential safety concerns, including an increased likelihood of brain swelling and bleeding, though long-term effects remain unclear.
The Alzheimer's Association has labeled the review 'scientifically flawed,' arguing it omits patient perspectives and real-world data. They assert that these treatments provide clinically meaningful slowing of disease progression for many patients. Pharmaceutical companies Lilly and Eisai have echoed these criticisms, asserting that the review inappropriately pools data from various drugs, diluting observed benefits for approved therapies like donanemab and lecanemab.
